PTK2 and melanoma: Exposure to 10 μM FAK inhibitor defactinib alone or combined with either dabrafenib or trametinib—depending on the mutation status—yielded 70–80% cell death in two mutBRAF (M53, M54) and two mutNRAS (M20, M32) melanoma samples, and improved cell death induction in M45 and M10 cells compared to the clinically relevant drug combination (Fig. 8B).